Newswise — WASHINGTON, DC – A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology’s 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
“About half of people with MS experience at some point in their life a condition called acute optic neuritis, in which the nerve carrying vision from the eye to the brain gets inflamed,” said study author Raj Kapoor, MD, with the National Hospital for Neurology and Neurosurgery in London, England. “The condition can cause sudden total or partial blindness, foggy or blackened vision and pain. Even though eyesight can recover eventually, each attack still damages the nerve and the eye.”
For the study, the researchers randomly selected 86 people with acute optic neuritis within two weeks of having symptoms to receive either the epilepsy drug phenytoin or a placebo for three months. The researchers then used medical imaging to measure the thickness of the retina, the light sensitive nerve layer at the back of the eye at the beginning of the study and then six months later. Each patient’s eyesight (including sharpness and color perception) was also tested.
The study found on average that the group who took phenytoin had 30 per cent less damage to the nerve fiber layer compared to those who received the placebo. The volume of the macula, the most light-sensitive part of the retina, was actually 34 percent higher in those who took phenytoin than those who received the placebo. As expected after a single attack, patients’ vision successfully recovered, and there weren’t any significant differences in visual outcomes over the long-term between the two treatment groups. “Eyesight is key to many important aspects of life, such as working, driving and participating in social activities,” said Kapoor. “If this finding is confirmed by larger studies, it could lead to a treatment that may prevent nerve damage and blindness in MS, and could help other attacks of MS, serving a major unmet need.”
The study was supported by the National Multiple Sclerosis Society, Multiple Sclerosis Society of Great Britain and Northern Ireland, an unrestricted grant from Novartis, the National Institute for Health Research Clinical Research Network and University College London Hospitals Biomedical Research Center.
To learn more about MS, please visit www.aan.com/patients.
The American Academy of Neurology, an association of more than 28,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.
Editor’s Note: Dr. Kapoor will present his findings at 12:00 p.m. ET, on Friday, April 24, 2015, in Ballroom AB of the Walter E. Washington Convention Center in Washington, DC.
Please contact Rachel Seroka, email@example.com, to schedule an advance interview.
To access Non-Emerging Science abstracts to be presented at the 2015 AAN Annual Meeting, visit http://www.abstracts2view.com/aan/. Emerging Science abstracts are embargoed until 12:01 a.m., ET, Friday, April 17, 2015, unless otherwise noted by the Academy’s Media and Public Relations Department.